Juan Paredes
@johnepm
Followers
426
Following
14K
Media
76
Statuses
1K
Gastroenterólogo del Hospital Nacional Guillermo Almenara Irigoyen Lima-Perú. Ex-Presidente de ASPEIN.
Lima
Joined October 2010
Buenas tardes estimados amigos. Anunciamos la próxima realización del ECCO Workshop en Lima el.29 de agosto del 2025. Evento organizado por ASPEIN y ECCO. Gracias @manu_barreiro
3
9
32
Non-invasive spectroscopic analytical molecular neural network-based p. Very interesting!!! @olga_nardone.
0
1
1
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study - Gastroenterology
gastrojournal.org
Guselkumab is a new treatment for improving Crohn’s disease with a patient-friendly administration option. Guselkumab injections resulted in meaningful improvements in symptoms and the lining of the...
0
0
0
RT @fgomollon: @Efuentesval @MartaCalvo12 @Bealoquebea @franlrs8 @frmoranta @geteccu @yzabanaa En nada. Trata bien, trata pronto y monitori….
0
4
0
Differential Outcomes of Early Versus Late Anti‐TNF Therapy in Ulcerative Colitis and Crohn's Disease: A Nationwide Propensity Score‐Matched Cohort Study - Oh - United European Gastroenterology Journal - Wiley Online Library
onlinelibrary.wiley.com
Background Early advanced inflammatory bowel disease (IBD) therapy is emphasised to prevent disease progression and restore quality of life. Aims To evaluate the potential advantages of early vers...
0
1
2
Alimentary Pharmacology & Therapeutics | Pharmacology Journal | Wiley Online Library
onlinelibrary.wiley.com
This study indirectly compares the efficacy of biologics and small molecule therapies in patients with Crohn's disease by investigating improvement in important treatment targets such as patient...
0
1
5
Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn’s Disease: A Systematic Review and Meta-analysis - Clinical Gastroenterology and Hepatology
cghjournal.org
We compared the efficacy of different advanced therapies by disease location in patients with Crohn’s disease (CD) through a systematic review and meta-analysis.
0
0
3
RT @EdwardLoftus2: Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease:….
academic.oup.com
AbstractBackground and Aims. The long-term efficacy and safety of upadacitinib in patients with moderate to severe Crohn’s disease (CD) were evaluated in t
0
24
0
RT @DeMadaria: Muy orgulloso de haber coordinado el comité de fluidoterapia en pancreatitis aguda de las nuevas guías de práctica clínica i….
0
4
0
RT @sped2025_lima: Prepárate para ser parte de nuestro programa científico en gastroenterología, diseñado para impulsar conocimientos y hab….
0
2
0
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-
thelancet.com
Intravenous induction followed by subcutaneous maintenance therapy with guselkumab was efficacious in participants with moderately to severely active Crohn's disease, showing superiority to placebo...
0
0
0
RT @UEGJournal: 🔥 #Burnout affects ~45% of #gastroenterologists & #endoscopists globally. 📉 A meta-analysis of 8,100+ professionals across….
0
12
0
RT @jalpa_devi: 🙏Help us reach our goal of ≥50 responses per country in our 🌍 #IBD survey! .📝 If you haven’t already, please take a moment….
0
20
0
Official journal of the American College of Gastroenterology | ACG
journals.lww.com
trial was conducted in 3 Canadian academic centers; randomized patients with mild-to-moderate CD received FMT or placebo. The first treatment was administered by colonoscopy followed by weekly oral...
0
0
1
RT @EndoCollabcom: TERMINAL ILEITIS DIFFERENTIAL DIAGNOSIS, By Dr. Paul Guzik.🔹Actinomycosis.🔹Amyloidosis.🔹Anisakiasis.🔹Ankylosing spondyli….
0
37
0
1
1
7
1
6
9
Real-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn’s Disease in the United States and Europe | Crohn's & Colitis 360 | Oxford Academic
academic.oup.com
AbstractBackground. Despite a wide range of available treatments, there is limited evidence as to why significant numbers of Crohn’s disease (CD) patients
0
0
0
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials - Clinical Gastroenterology and Hepatology
cghjournal.org
Efficacy of upadacitinib, an oral Janus kinase inhibitor, for moderate-to-severe Crohn’s disease was demonstrated in phase 3 induction (U-EXCEL, U-EXCEED) and maintenance (U-ENDURE) trials; this post...
0
0
1